<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="8860">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02991612</url>
  </required_header>
  <id_info>
    <org_study_id>ZS-CSY-RFXM</org_study_id>
    <nct_id>NCT02991612</nct_id>
  </id_info>
  <brief_title>Rifaximin in Patients With Gastroesophageal Variceal Bleeding</brief_title>
  <acronym>RFXM</acronym>
  <official_title>Efficacy of Rafiximin in Patients With Cirrhotic Gastroesophageal Variceal Hemorrhage: A Single-center Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Zhongshan Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Zhongshan Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the safety and efficacy of Rifaximin in the
      treatment of cirrhotic gastroesophageal variceal bleeding.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Gastroesophageal variceal bleeding is the most common and life-threatening condition in
      patients with portal hypertension, which are susceptibility to bacterial infection.

      However, the prophylaxis use of antibiotics remained uncertain and lack of high level
      evidences.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2016</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of all clinical adverse events</measure>
    <time_frame>8 weeks</time_frame>
    <description>The occurrence of rebleeding, ascites fluid infection, hepatorenal syndrome, hepatopulmonary syndrome, portal vein thrombosis, or death in 8 weeks</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of all clinical adverse events</measure>
    <time_frame>6 months</time_frame>
    <description>The occurrence of rebleeding, ascites fluid infection, hepatorenal syndrome, hepatopulmonary syndrome, portal vein thrombosis, or death in 6 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of intestinal flora</measure>
    <time_frame>2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The changes of plasma endotoxins level</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Cirrhosis</condition>
  <condition>Esophageal and Gastric Varices</condition>
  <condition>Gastrointestinal Hemorrhage</condition>
  <arm_group>
    <arm_group_label>Rifaximin Treatment Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rifaximin 400mg bid for 2 months,</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Receive routine endoscopic treatment without having rifaximin for 2 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rifaximin</intervention_name>
    <description>Patients receive Rifaximin 400mg bid for 2 months</description>
    <arm_group_label>Rifaximin Treatment Group</arm_group_label>
    <other_name>XIFAXAN</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 y.o. ≤age≤75 y.o.;

          -  Cirrhotic gastroesophageal variceal bleeding underwent endoscopic treatment (include
             esophageal varices ligation, endoscopic injection sclerosis and gastric N-
             butyl-cyanoacrylate injection).

        Exclusion Criteria:

          -  age &lt;18 y.o. or age &gt; 75 y.o.;

          -  Never had the variceal bleeding episode before;

          -  Do not have endoscopic treatment;

          -  combined with other malignant tumor (not exclude patients with hepatocellular
             carcinoma who don't not need treatment at the moment);

          -  Known infection after endoscopic treatment (Fever, microbial cultures positive, et
             al.)

          -  Massive ascites or combined with other high risk factor that require prophylaxis use
             of antibiotics.

          -  Acute variceal bleeding within 5 days.

          -  Use of other antibiotics in the past 2 weeks;

          -  Refuse to participate
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shiyao CHEN, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Zhongshan Hospital, Fudan University, Shanghai</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xiaoquan HUANG, M.D.</last_name>
    <phone>18801733835</phone>
    <email>huangxiaoquan1010@aliyun.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Shiyao CHEN, M.D.</last_name>
    <phone>13601767310</phone>
    <email>chen.shiyao@zs-hospital.sh.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>180 Fenglin Road</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaoquan HUANG, M.D.</last_name>
      <phone>+86-18801733835</phone>
      <email>huangxiaoquan1010@aliyun.com</email>
    </contact>
    <investigator>
      <last_name>Shiyao Chen, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <lastchanged_date>December 29, 2016</lastchanged_date>
  <firstreceived_date>December 10, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Zhongshan Hospital</investigator_affiliation>
    <investigator_full_name>Shiyao Chen</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Gastrointestinal Hemorrhage</mesh_term>
    <mesh_term>Esophageal and Gastric Varices</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Rifaximin</mesh_term>
    <mesh_term>Rifamycins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
